Drug Trial Radar · NCT07614646
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
13
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jul 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Everest Medicines (Beijing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) combination with Ivonescimab in patients with sq-NSCLC.
Conditions
- Squamous Non-Small Cell Lung Cancer sqNSCLC
Interventions
EVM14Biological
Cancer Vaccine, Intramuscular (IM) injection at escalating dose levels, administered once every 3 weeks (Q3W)
IvonescimabBiological
Anti PD 1/VEGF bispecific antibody, administered intravenously at a dose of 200 mg once every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicity (DLT)Time frame: 21days since the 1st EVM14 dose
- Incidence and severity of TEAE, TRAE, SAEs, and adverse events (AEs) of Grade ≥ 3Time frame: From first dose until 30±7 days post-last dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.